Activation of the alternative complement pathway by human B cell lymphoma lines is associated with Epstein-Barr virus transformation of the cells
- PMID: 211040
- DOI: 10.1002/eji.1830080702
Activation of the alternative complement pathway by human B cell lymphoma lines is associated with Epstein-Barr virus transformation of the cells
Abstract
Activation of the alternative complement pathway by human B cell lymphoma lines is correlated with the presence of Epstein Barr virus (EBV) in the cell genome. EBV-negative B cell lymphoma lines produce little activation of the alternative pathway as measured either by C3 deposition on the cell surface or C3 conversion and consumption of alternative pathway activity in the supernatant serum. By contrast, EBV-positive sublines derived by in vitro EBV conversion of EBV-negative parental lines produce considerable activation of the alternative pathway. This membrane-associated complement-activating mechanism reflects an EBV-induced membrane change in these cells and may provide a mechanism whereby EBV-transformed cells are controlled in vivo.
Similar articles
-
Alternative pathway of complement activation by human lymphoblastoid B and T cell lines.J Immunol. 1983 Sep;131(3):1396-9. J Immunol. 1983. PMID: 6604099
-
Production of nephritic factor of the alternative complement pathway by Epstein Barr virus-transformed B cell lines derived from a patient with membranoproliferative glomerulonephritis.J Immunol. 1986 Jun 15;136(12):4451-5. J Immunol. 1986. PMID: 3011894
-
Activation of the alternative complement pathway by EBV and the viral envelope glycoprotein, gp350.J Immunol. 1988 Jun 1;140(11):3867-74. J Immunol. 1988. PMID: 2836501
-
T cell recognition of Epstein-Barr virus associated lymphomas.Cancer Surv. 1992;13:53-80. Cancer Surv. 1992. PMID: 1330300 Review.
-
Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.Autoimmunity. 2008 May;41(4):298-328. doi: 10.1080/08916930802024772. Autoimmunity. 2008. PMID: 18432410 Review.
Cited by
-
Evidence for activation of complement in patients with AIDS related complex (ARC) and/or lymphoadenopathy syndrome (LAS).Clin Exp Immunol. 1987 Dec;70(3):500-7. Clin Exp Immunol. 1987. PMID: 3436097 Free PMC article.
-
Complement as a Biological Tool to Control Tumor Growth.Front Immunol. 2018 Sep 25;9:2203. doi: 10.3389/fimmu.2018.02203. eCollection 2018. Front Immunol. 2018. PMID: 30319647 Free PMC article. Review.
-
Destruction of virus infected cells by neutrophils and complement.Experientia. 1980 Mar 15;36(3):352-4. doi: 10.1007/BF01952322. Experientia. 1980. PMID: 6245915
-
Epstein-Barr virus (EBV), lymphocytes and transformation.J Cancer Res Clin Oncol. 1983;106(1):1-11. doi: 10.1007/BF00399890. J Cancer Res Clin Oncol. 1983. PMID: 6309856 Free PMC article. Review. No abstract available.
-
Neutralizing antiviral antibody responses.Adv Immunol. 2001;79:1-53. doi: 10.1016/s0065-2776(01)79001-3. Adv Immunol. 2001. PMID: 11680006 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous